BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY) today announced three presentations of lanreotide data to be shared at the 2015 Gastrointestinal Cancers Symposium, January 15-17, 2015 in San Francisco, CA. One oral and two poster presentations will explore the use of lanreotide in gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), including sub analyses of the pivotal Phase III, multinational, randomized, double-blind clinical trial (CLARINET®).
An oral presentation titled Effects of lanreotide Autogel/Depot (LAN) in pancreatic neuroendocrine tumors (pNETs): a subgroup analysis from the CLARINET study will be delivered by Dr. Alexandria Phan of Houston Methodist Hospital on Friday, January 16 at the Level 2 Ballroom from 5:00-5:10 pm PST.
Help employers find you! Check out all the jobs and post your resume.
An oral presentation titled Effects of lanreotide Autogel/Depot (LAN) in pancreatic neuroendocrine tumors (pNETs): a subgroup analysis from the CLARINET study will be delivered by Dr. Alexandria Phan of Houston Methodist Hospital on Friday, January 16 at the Level 2 Ballroom from 5:00-5:10 pm PST.
Help employers find you! Check out all the jobs and post your resume.
